PL3442578T3 - Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów - Google Patents

Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów

Info

Publication number
PL3442578T3
PL3442578T3 PL17783254T PL17783254T PL3442578T3 PL 3442578 T3 PL3442578 T3 PL 3442578T3 PL 17783254 T PL17783254 T PL 17783254T PL 17783254 T PL17783254 T PL 17783254T PL 3442578 T3 PL3442578 T3 PL 3442578T3
Authority
PL
Poland
Prior art keywords
cancer
agents
determining
treatment
methods
Prior art date
Application number
PL17783254T
Other languages
English (en)
Inventor
Irving L. Weissman
Mark P. Chao
Ravindra Majeti
Jie Liu
Jens-Peter VOLKMER
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of PL3442578T3 publication Critical patent/PL3442578T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL17783254T 2016-04-15 2017-04-14 Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów PL3442578T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US201662427679P 2016-11-29 2016-11-29
EP17783254.0A EP3442578B1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer

Publications (1)

Publication Number Publication Date
PL3442578T3 true PL3442578T3 (pl) 2022-06-20

Family

ID=60042716

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17783254T PL3442578T3 (pl) 2016-04-15 2017-04-14 Sposoby określania i osiągania terapeutycznie skutecznych dawek środków anty-cd47 w leczeniu nowotworów

Country Status (12)

Country Link
US (3) US11472878B2 (pl)
EP (3) EP3442578B1 (pl)
JP (3) JP7532009B2 (pl)
KR (3) KR20240016445A (pl)
CN (3) CN117695387A (pl)
AU (2) AU2017250809B2 (pl)
CA (1) CA3019676A1 (pl)
ES (1) ES2909835T3 (pl)
PL (1) PL3442578T3 (pl)
PT (1) PT3442578T (pl)
SI (1) SI3442578T1 (pl)
WO (1) WO2017181033A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3534965A4 (en) 2016-11-03 2020-06-24 Trillium Therapeutics Inc. IMPROVEMENTS IN CD47 BLOCKADERAPY THROUGH HDAC INHIBITORS
KR20200068730A (ko) 2017-10-18 2020-06-15 포티 세븐, 인코포레이티드 항-cd47 작용제-기초된 난소암 요법
PL3752190T3 (pl) * 2018-02-12 2022-11-07 Forty Seven, Inc. „schemat przeciwnowotworowy z wykorzystaniem przeciwciał anty-cd47 i anty-cd20
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
AU2019349651B2 (en) 2018-09-27 2023-12-07 Celgene Corporation SIRP alpha binding proteins and methods of use thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
MX2021006134A (es) 2018-11-26 2021-06-23 Forty Seven Inc Anticuerpos humanizados contra c-kit.
AU2019390394B2 (en) 2018-11-28 2023-11-30 Forty Seven, Inc. Genetically modified HSPCs resistant to ablation regime
RS65480B1 (sr) 2019-09-18 2024-05-31 Lamkap Bio Alpha AG Bispecifična antitela protiv ceacam5 i cd3
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
WO2021206965A1 (en) * 2020-04-06 2021-10-14 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation
WO2022140659A2 (en) 2020-12-23 2022-06-30 D-10 Therapeutics, Inc. Anti-cd47 antibodies and uses thereof
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3056514T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação de fagocitose mediada por cd47
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
RS60606B1 (sr) 2012-01-17 2020-08-31 Univ Leland Stanford Junior Reagensi sirp-alfa visokog affiniteta
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
BR112015018851A2 (pt) 2013-02-06 2017-07-18 Inhibrx Llc anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos
PT2970493T (pt) * 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
CN105143876B (zh) 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
CA2910466A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
EP3052119B1 (en) 2013-10-01 2018-08-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
WO2015105995A2 (en) 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
EP3204420B1 (en) * 2014-10-10 2020-09-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods to eliminate cancer stem cells by targeting cd47
WO2021206965A1 (en) * 2020-04-06 2021-10-14 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation

Also Published As

Publication number Publication date
JP7532009B2 (ja) 2024-08-13
JP2022172278A (ja) 2022-11-15
EP4074339A1 (en) 2022-10-19
EP3442578A4 (en) 2019-04-10
EP4349412A2 (en) 2024-04-10
JP7442591B2 (ja) 2024-03-04
US20230406923A1 (en) 2023-12-21
ES2909835T3 (es) 2022-05-10
KR102505253B1 (ko) 2023-03-02
PT3442578T (pt) 2022-05-19
EP4349412A3 (en) 2024-06-12
KR20240016445A (ko) 2024-02-06
CN117695387A (zh) 2024-03-15
SI3442578T1 (sl) 2022-05-31
WO2017181033A1 (en) 2017-10-19
US11472878B2 (en) 2022-10-18
CN115350276A (zh) 2022-11-18
US11718670B2 (en) 2023-08-08
AU2017250809B2 (en) 2024-02-29
CN109152837A (zh) 2019-01-04
EP3442578A1 (en) 2019-02-20
JP2019515899A (ja) 2019-06-13
AU2017250809A1 (en) 2018-10-25
JP2024059764A (ja) 2024-05-01
EP3442578B1 (en) 2022-02-09
KR20180134367A (ko) 2018-12-18
KR20230035435A (ko) 2023-03-13
US20190106491A1 (en) 2019-04-11
US20230068235A1 (en) 2023-03-02
CA3019676A1 (en) 2017-10-19
AU2024203396A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
PT3442578T (pt) Métodos para determinar e alcançar doses terapêuticas eficazes de agentes anti-cd47 no tratamento do cancro
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
HK1257249A1 (zh) 使用脂質體伊立替康和parp抑制劑用於癌症治療的組合療法
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
IL266198A (en) Liposomal formulation for use in cancer treatment
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
IL266182A (en) Farensyltransferase inhibitors for use in cancer treatment methods
HK1245096A1 (zh) 用於癌症治療的細胞治療劑以及使用該細胞治療劑的聯合治療
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
PT3325478T (pt) Novo composto terapêutico e a utilização em terapia
GB201600637D0 (en) Therapeutic treatment methods and apparatus for use therein
GB201612793D0 (en) Therapeutic use of quesnoin in colorectal cancer treatment
GB201612794D0 (en) Therapeutic use of diethanololeamide in prostate cancer treatment
AU2016905362A0 (en) Compounds and use thereof in methods of treatment
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201418640D0 (en) Agents and methods for treatment of cancer